Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

08-06-2021 | ASCO 2021 | Conference coverage | Video

Three-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer

Amit Bahl explains why 3-weekly cabazitaxel is still a valid option for treatment-naïve, HER2-negative, metastatic breast cancer even though the CONCEPT trial failed to show its superiority over weekly paclitaxel in this setting (7:14).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Image Credits